Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
3(30%)
Results Posted
0%(0 trials)
Terminated
2(20%)

Phase Distribution

Ph not_applicable
6
60%
Ph phase_1
3
30%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
N/ANon-phased studies
6(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

3

trials recruiting

Total Trials

10

all time

Status Distribution
Active(3)
Completed(4)
Terminated(3)

Detailed Status

Completed4
Terminated2
Recruiting2
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
3
Success Rate
66.7%
Most Advanced
Phase 1

Trials by Phase

Phase 13 (33.3%)
N/A6 (66.7%)

Trials by Status

terminated220%
active_not_recruiting110%
completed440%
recruiting220%
withdrawn110%

Recent Activity

3 active trials
Showing 5 of 10
active_not_recruitingnot_applicable

Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

NCT01644669
recruitingphase_1

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer

NCT02977468
recruiting

Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer

NCT04603209
terminatednot_applicable

Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT

NCT04763031
completednot_applicable

Intraoperative Radiation Therapy for Resectable Pancreatic Cancer

NCT03273374
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT01644669Not Applicable

Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

Active Not Recruiting
NCT02977468Phase 1

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer

Recruiting
NCT04603209

Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer

Recruiting
NCT04763031Not Applicable

Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT

Terminated
NCT03273374Not Applicable

Intraoperative Radiation Therapy for Resectable Pancreatic Cancer

Completed
NCT04349111Not Applicable

An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite"

Withdrawn
NCT01566123Phase 1

Trial of Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma (RETRO-WTS)

Completed
NCT02040493Not Applicable

Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer

Terminated
NCT01988870Not Applicable

IORT (Intra-operative Radiation Therapy) in Early Stage Breast Cancer

Completed
NCT00004123Phase 1

Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma

Completed

All 10 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
10